Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients

This Danish cohort study tested, in real-world statin-treated patients, which lipid measure best flags the risk that remains despite treatment — and delivered a clear verdict for apolipoprotein B and non-HDL cholesterol over LDL.

Among statin-treated patients, high apoB and high non-HDL cholesterol each predicted increased heart attack and all-cause mortality, while high LDL cholesterol did not. The discordance analysis was the clincher: patients with high apoB but low LDL had significantly elevated risk of heart attack and death, whereas those with high LDL but low apoB did not. When the markers disagree, apoB tells the truth.

This is among the most direct demonstrations that LDL cholesterol can falsely reassure in treated patients, and that apoB (or non-HDL) should guide assessment of residual risk.

We rate the evidence strong. A well-conducted prospective cohort with a clean discordance design, it provides real-world support for the apoB-centric approach that consensus statements increasingly endorse.